Hemmelrather Weg 201
61 articles about Biofrontera AG
Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts
Biofrontera Inc. announced the appointment of Samantha Widdicombe to the newly created position of Senior Director, Strategic Accounts and Communications.
Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma
Biofrontera Inc. announces that patient enrollment is now complete in the Phase 3 clinical study evaluating Ameluz -PDT in combination with the BF-RhodoLED lamp for the treatment of basal cell carcinoma (BCC).
Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatologic products, announces that its Board of Directors has named Hermann Luebbert as Chief Executive Officer.
Biofrontera Inc. announced that it has entered into a $6.5 million secured line of credit with MidCap Business Credit, LLC, subject to the borrowing base formula, minimum excess availability and other terms and conditions.
Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)
Biofrontera Inc. today announced that that the last patient in a Phase I study to evaluate the safety and tolerability of Ameluz.
Biofrontera Inc. announced that it will be hosting a booth showcasing its innovative, FDA-approved products at the 2023 American Academy of Dermatology Annual Meeting taking place March 17-21, 2023 in New Orleans, LA.
CORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results
This press release corrects and replaces the press release published on 3/8/2023 at 4:03:00 PM ET, as the Adjusted EBITDA Reconciliation table was not included in all previously posted versions of the press release.
Biofrontera Inc. today announced that it will report financial results for the three and 12 months ended December 31, 2022 on Wednesday, March 8, 2023.
Biofrontera Inc. announced that the Company will be participating in Benchmark’s 11th Annual Discovery One-on-One Investor Conference being held on December 1, 2022 in New York, NY.
Biofrontera Inc today announced financial results for the three and nine months ended September 30, 2022 and provided a business update.
Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatological products, announced the exercise in full of options to purchase 2,623,365 ordinary shares of Biofrontera AG.
New Movers & Shakers took over the roles of chief executive officer, chief financial officer, chief medical officer and more at companies including Scenic Biotech, Biofrontera and X4 Pharmaceuticals.
Biofrontera Inc. announces the appointment of Fred Leffler as Chief Financial Officer, effective immediately.
Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatological products, announces its sponsorship of the Fall Clinical Dermatology Conference, being held October 20-23 in Las Vegas.
Biofrontera Inc. announced that its Board of Directors has adopted a limited duration shareholder rights plan, and declared a dividend distribution of one preferred stock purchase right on each outstanding share of common stock, in order to protect the interest of all of the Company’s shareholders.
Biofrontera Inc. today announced preliminary unaudited product revenues for the three and nine months ended September 30, 2022.
Biofrontera Inc. announced that PM360, a publication for marketing decision makers in the pharmaceutical, biotech, diagnostics and medical device industries, has awarded the previously nominated Ameluz® marketing campaign, created by Biofrontera Inc. along with Elevate Healthcare, “Relaunch/Revitalization of the Year” and “Professional Website/Online Initiative of the Year” awards.
This week's Movers & Shakers include Arvinas, Inspire and Cambridge Isotope Laboratories all announcing new VP roles, and several others tap new C-suite executives.
Biofrontera Inc. announced that PM360, a publication for marketing decision makers in the pharmaceutical, biotech, diagnostics and medical device industries, has named Leslie Hopkins, Associate Director of Marketing, as a Trailblazer Brand Champion in the Dermatology category.
Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH
Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Australian Patent Office (IP Australia) granted a notice of allowance to Biofrontera Bioscience GmbH for the patent "Photodynamic therapy comprising two light exposures at different wavelengths" (AU 2018/437303B2).